

AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior versions and listings of the claims for this application. Within this listing of the claims, claims 78-83 and 88-91 have been canceled; claims 68 and 92 have been amended; and claims 93-99 are new.

68. **(Currently Amended)** A ~~topical~~ pharmaceutical formulation for use in ~~preventing or~~ treating skin conditions, disorders and diseases associated with inflammation, comprising a ~~topical carrier and~~ a therapeutically effective concentration of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing, wherein the ~~skin condition, disorder, or disease is selected from the group consisting of psoriasis, contact dermatitis, atopic dermatitis, actinic keratosis, keratinization disorders, epidermolysis bullosa diseases, exfoliative dermatitis, seborrheic dermatitis, erythemas, discoid lupus erythematosus, dermatomyositis, dermatomyositis, and skin cancer~~ pharmaceutical formulation is a microemulsion for oral or parenteral administration.

69. **(Original)** The formulation of claim 68, wherein the active agent is *cis*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

70. **(Original)** The formulation of claim 69, wherein the active agent is *cis*-resveratrol.

71. **(Original)** The formulation of claim 69, wherein the active agent is a conjugate of *cis*-resveratrol and a mono- or di-saccharide.

72. **(Original)** The formulation of claim 71, wherein the active agent is *cis*-resveratrol glucoside.

73. **(Original)** The formulation of claim 68, wherein the active agent is *trans*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

74. **(Original)** The formulation of claim 73, wherein the active agent is *trans*-resveratrol.

75. **(Original)** The formulation of claim 74, wherein the active agent is a conjugate of *trans*-resveratrol and a mono- or di-saccharide.

76. **(Original)** The formulation of claim 75, wherein the active agent is *trans*-resveratrol glucoside.

77. **(Original)** The formulation of claim 68, wherein the active agent comprises a mixture of *cis*-resveratrol and *trans*-resveratrol.

78-83. **(Canceled)**

84. **(Original)** The formulation of claim 68, comprising approximately 0.25 wt.% to 75 wt.% active agent.

85. **(Original)** The formulation of claim 84, comprising approximately 0.25 wt.% to 30 wt.% active agent.

86. **(Original)** The formulation of claim 85, comprising approximately 0.5 wt.% to 15 wt.% active agent.

87. **(Original)** The formulation of claim 86, comprising approximately 1.0 wt.% to 10 wt.% active agent.

88-91. **(Canceled)**

92. **(Currently amended)** A topical pharmaceutical formulation for inhibiting cellular events associated with tumor initiation, promotion, and progression, comprising a ~~topical carrier~~ and a therapeutically effective concentration of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs and analogs thereof, and combinations of any of the foregoing, wherein the pharmaceutical formulation is a microemulsion for oral or parenteral administration.

93. (New) The pharmaceutical formulation of claim 68, wherein the skin condition, disorder, or disease is selected from the group consisting of psoriasis, contact dermatitis, atopic dermatitis, actinic keratosis, keratinization disorders, epidermolysis bullosa diseases, exfoliative dermatitis, seborrheic dermatitis, erythemas, discoid lupus erythematosus, dermatomyositis, and skin cancer.

94. (New) The pharmaceutical formulation of claim 68, wherein the microemulsion is comprised of a surfactant, a co-surfactant, an oil phase, and a water phase.

95. (New) The pharmaceutical formulation of claim 94, wherein the surfactant is selected from the group consisting of glyceryl monostearate, polyethylene glycol, caprylic triglycerides, and capric triglycerides.

96. (New) The pharmaceutical formulation of claim 94, wherein the co-surfactant is selected from the group consisting of polyoxyethylene stearate, and ethylene glycol palmitostearate, and oleoyl macrogolglycerides.

97. (New) The pharmaceutical formulation of claim 94, wherein the oil phase is selected from the group consisting of fatty acid esters, modified vegetable oils, silicone oils, monoglycerides, diglycerides, triglycerides, and oleoyl macrogol glycerides.

98. (New) The pharmaceutical formulation of claim 94, wherein the water phase is selected from the group consisting of water, buffers, glucose, propylene glycol, polyethylene glycols, and glycerol.

99. (New) The pharmaceutical formulation of claim 68, further comprising a pharmaceutically acceptable carrier suited for oral or parenteral drug administration.